Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biora Therapeutics, Inc. - Common Stock (NQ: BIOR )

0.6899 +0.0099 (+1.46%)
Streaming Delayed Price Updated: 3:06 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 88,764
Open 0.6900
Bid (Size) 0.6707 (7)
Ask (Size) 0.6899 (6)
Prev. Close 0.6800
Today's Range 0.6701 - 0.6980
52wk Range 0.4750 - 3.380
Shares Outstanding 4,063,081
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biora Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q2 2024
BIOR stock results show that Biora Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-48.13%
-48.13%
1 Month
+3.32%
+3.32%
3 Month
+13.84%
+13.84%
6 Month
-34.30%
-34.30%
1 Year
-74.54%
-74.54%

More News

Read More
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Funding Agreement with Existing Investors
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report Second Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
BIOR Stock Earnings: Biora Therapeutics Beats EPS for Q1 2024
Via InvestorPlace
Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap™ Oral Delivery Platform at Digestive Disease Week 2024
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
From Biora Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Biora Therapeutics Announces New Patent Covering its BioJet™ Liquid Jet Delivery Technology
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
From Biora Therapeutics, Inc.
Via GlobeNewswire
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
From Biora Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.